OncoMed begins dosing GITRL-Fc in Phase Ia trial for solid tumours

US-based OncoMed Pharmaceuticals has begun dosing patients in a Phase Ia clinical trial of its therapeutic candidate GITRL-Fc (OMP-336B11) to treat patients suffering from solid tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news